Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Issues 8.3M in Bonds for Clinical Development

NEW YORK, Feb. 2 (GenomeWeb News) - ExonHit Therapeutics has issued €8.3 million ($10.3 million) in convertible bonds to existing shareholders and affiliate companies, the Paris-based company said today.

 

The funding will allow ExonHit to operate into 2006 and to conduct clinical trials. The company focuses on alternative RNA splicing, using a gene profiling technology to identify RNA splicing alternatives on a genome-wide scale.

 

ExonHit plans to develop therapeutics and diagnostics for neurodegenerative diseases and cancer. In 2001, the company raised €30 million in a private financing round.

 

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.